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Alzheimer’s disease (AD) is associated with cognitive and non-cognitive symptoms for
which there are currently no effective therapies. We have previously reported that
cotinine, a natural product obtained from tobacco leaves, prevented memory loss and
diminished amyloid-β (Aβ) plaque pathology in transgenic 6799 mice (Tg6799 mice)
when treated prior to the development of the pathology. We have also shown that
cotinine reduces depressive-like behavior in normal and chronically stressed C57BL/6
mice. Here, we extend our previous studies by investigating the effects of cotinine on the
progression of AD-like pathology, depressive-like behavior, and the mechanisms underlying
its beneficial effects in Tg6799 mice when left untreated until after a more advanced
stage of the disease’s development. The results show that vehicle-treated Tg6799 mice
displayed an accentuated loss of working memory and an abundant Aβ plaque pathology
that were accompanied by higher levels of depressive-like behavior as compared to
control littermates. By contrast, prolonged daily cotinine treatment to Tg6799 mice,
withheld until after a mid-level progression of AD-like pathology, reduced Aβ levels/plaques
and depressive-like behavior. Moreover, this treatment paradigm dramatically improved
working memory as compared to control littermates. The beneficial effects of cotinine
were accompanied by an increase in the expression of the active form of protein kinase B
and the postsynaptic density protein 95 in the hippocampi and frontal cortices of Tg6799
mice. This suggests that cotinine halts the progression of AD-like pathology while reducing
depressive-like behavior by stimulating signaling pathways supporting synaptic plasticity in
Tg6799 mice. The potential use of cotinine to treat cognitive and non-cognitive symptoms
of AD is discussed.
Keywords: Alzheimer’s disease, amyloid-β, cotinine, depression, memory loss, postsynaptic density protein 95,
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Abbreviations: Aβ, amyloid-β; AChE, acetylcholinesterase; AD, Alzheimer’s
disease; Akt (PKB), protein kinase B; APP, amyloid precursor protein;
ANOVA, analysis of variance; BDNF, brain-derived neurotrophic factor, CaMKK,
calmodulin-dependent protein kinase kinase; 4EBP1, eukaryotic translation initi-
ation factor 4E-binding protein 1; ELISA, enzyme-linked immunosorbent assay,
ERK, extracellular signal-regulated kinase; eIF4E, eukaryotic translation initia-
tion factor 4E; GSK3β; glycogen synthase kinase 3β; FAD, familial AD; FS, forced
swim; 5-HT, serotonin; IHC, immunohistochemical; MAOIs, monoamine oxidase
inhibitors; mTOR, mammalian target of rapamycin; NFT, neurofibrillary tangle;
nAChRs, nicotinic acetylcholine receptors; NMDA, N-methyl-D-aspartate; NT,
non-transgenic; OF, open field; PAM, positive allosteric modulator; PI3K, phos-
phatidylinositol 3-kinase; PS1, presenilin 1; PSD95, postsynaptic density protein
95; PT, Porsolt’s forced swim test; RAWM, radial arm water maze; RIPA, radioim-
munoprecipitation assay; SAD, sporadic AD; SSRIs, selective serotonin reuptake
inhibitors; SNRIs, serotonin norepinephrine reuptake inhibitors; T, trial; TBST,
Tris-buffered saline with 0.05% tween 20; TST, tail suspension test.
INTRODUCTION
Alzheimer’s disease (AD) is a devastating neurodegenerative dis-
ease and the major cause of dementia worldwide (Stone et al.,
2011). It is estimated that well over 25 million people suffer from
dementia today with one new case diagnosed every 7 s (Ferri et al.,
2005). The number of individuals affected in developed countries
are expected to double in the United States and triple in both
India and China as well as their south Asian and western pacific
neighbors over the next three decades (Ferri et al., 2005). Drugs
currently used to treat AD, such as acetylcholinesterase (AChE)
inhibitors and the N-methyl-D-aspartate (NMDA) antagonists,
have only modest effects in delaying the progression of the disease
(Starkstein and Mizrahi, 2006; Hansen et al., 2007; Raina et al.,
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2008). Moreover, the tolerability of these drugs is compromised
by their side effects, for instance dizziness, anorexia, vomiting,
and diarrhea (Alva and Cummings, 2008).
In patients suffering from AD, there is a high incidence of
depression (∼50%) that precedes (Meynen et al., 2007; Modrego,
2010; Vilalta-Franch et al., 2013) and may accelerate the clin-
ical evolution of the disease (Starkstein and Mizrahi, 2006;
Hou et al., 2010; Aznar and Knudsen, 2011; Raudino, 2013;
Theleritis et al., 2013). Depression in AD is linked with ear-
lier admission to nursing homes and increased mortality (Even
and Weintraub, 2010). Unfortunately, commonly used antide-
pressants such as fluoxetine and sertraline (Weintraub et al.,
2010) have only marginal short-term effects on depressive symp-
toms related to AD (Modrego, 2010). In addition, the alternative
use of antipsychotics as an antidepressant in the elderly popula-
tion has been questioned for safety reasons (Assal and van der
Meulen, 2009; Gardette et al., 2012). The failure of these com-
monly used antidepressants can be explained by the fact that
depression in AD patients has characteristics that differ from its
expression in other conditions (Hollingworth et al., 2006). It is
therefore imperative to investigate the effectiveness of novel drugs
with better safety profiles to treat cognitive and non-cognitive
symptoms in AD (Alva and Cummings, 2008). In doing so,
such compounds can greatly decrease the extra burden in care-
giving (Deimling and Bass, 1986), rates of institutionalization
(Steele et al., 1990), and overall associated financial costs (Cohen-
Mansfield, 1995). To the best of our knowledge, drugs reducing
both cognitive and non-cognitive symptoms in AD have not been
described.
We have previously shown that cotinine, a natural product
obtained from tobacco leaves and the predominant metabolite of
nicotine, improved memory and reduced amyloid-β (Aβ) plaque
pathology in a transgenic 6799 mouse (Tg6799 mouse) model
of AD when treatment began prior to the disease’s develop-
ment (Echeverria et al., 2011). Tg6799 mice express the human
amyloid precursor protein (APP) and presenilin 1 (PS1) genes
containing three familial AD (FAD) mutations in APP and
two in PS1 (Oakley et al., 2006; Ohno et al., 2006). Cotinine
also reduces depressive-like behavior in normal and chronically
stressed C57BL/6 mice (Grizzell et al., 2014). Furthermore, coti-
nine stimulates protein kinase B (Akt) and inhibits the glycogen
synthase kinase 3β (GSK3β) in the brains of stressed C57BL/6
(Grizzell et al., 2014) and Tg6799 mice (Echeverria et al., 2011).
Here, we investigated the effect of cotinine on working mem-
ory and Aβ plaque deposition in the brains of Tg6799 mice
when treatment was withheld until more advanced stages of the
AD-like pathology. Additionally, we sought to determine if coti-
nine’s aforementioned antidepressant effects in C57BL/6 mice
extend to Tg6799 mice following only 10 days of treatment. To
better understand the molecular mechanisms involved in coti-
nine’s actions, we also investigated whether cotinine stimulates
the Akt/postsynaptic density protein 95 (PSD95) pathway, which
plays a central role in mediating synaptic plasticity improvement
induced by antidepressants and cognitive enhancers. The new
evidence described in this report suggests that cotinine may rep-
resent a therapeutic agent to treat cognitive and non-cognitive
symptoms in AD.
MATERIALS AND METHODS
ANIMALS
All experiments were performed using Tg6799 mice (5 × FAD)
which express the human APP and PS1 genes, containing five
FADmutations (Oakley et al., 2006), three in APP (Swedishmuta-
tion: K670N,M671L; Floridamutation: I716V; Londonmutation:
V717I) and two in PS1 (M146L, L286V) (Ohno et al., 2006). The
Tg6799 line mice were maintained as hemizygotes on a C57BL/6J
hybrid background (The Jackson Laboratories, Bar Harbor, ME).
Male mice were used as heterozygotes with respect to the trans-
gene and non-transgenic (NT) wild-type littermates served as
controls. Mice were maintained on a 12:12 light-dark cycle with
ad libitum access to food and water. Protocols were performed
with the approval of the Institutional Animal Care and Use
Committees of the University of South Florida and the Bay Pines
Veterans Affairs Healthcare System.
COTININE TREATMENT
Cotinine [(5S)-1-methyl-5-(3-pyridyl)-pyrrolidin-2-one] was
obtained from Sigma-Aldrich (Saint Louis, MO). Mice began
daily oral treatment with cotinine (5mg/kg; Cot 5), dissolved in
phosphate buffer saline (PBS, pH 7.4) or vehicle (PBS alone),
via gavage between 4.5–5 months of age and were treated
continuously until euthanasia. The dose used in this study was
chosen based in our previous AD studies showing that a dose of
cotinine 2.5mg/kg prevented cognitive impairment and reduced
Aβ plaque formation in Tg6799 mice (Zeitlin et al., 2012). From
parallel studies testing the effect of cotinine on depressive-like
behavior, we have observed that cotinine (5mg/kg) consistently
decreased depressive-like behavior in wild-type mice as well as
in several models of psychological stress (Grizzell et al., 2014).
Thus, to target both cognitive and non-cognitive symptoms, we
have tested this dose Cot 5mg/kg in mice.
EXPERIMENTAL CONDITIONS
Protocol 1
Tg6799 mice and NT littermates (∼5 months of age) were treated
with cotinine or vehicle (n = 8 per group) for 3 months and
tested for spatial/working memory deficits in the radial arm water
maze (RAWM) (Arendash et al., 2009; Grizzell et al., 2014) for 8
consecutive days. Following RAWM testing, mice were euthanized
and brains were collected for Western blot analysis (Figure 1A).
Protocol 2
Tg6799 mice and NT littermates (∼5 months of age) were treated
for 2 months with cotinine or vehicle (n = 8 per group), eutha-
nized, and brains were collected for immunohistochemical (IHC)
analysis (Figure 2A).
Protocol 3
Tg6799 mice and NT littermates (∼5 months of age; n = 16
per group) were tested for basal depressive-like behavior using
Porsolt’s forced swim test (PT; basal= PT-1). Following 10 days of
cotinine or vehicle treatment in Tg6799 mice (n = 8 per group),
the effects of cotinine on depressive-like behavior in the PT was
tested again (PT-2; Figure 3A).
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FIGURE 1 | Cotinine prevented cognitive impairment in Tg6799 mice.
4.5–5 month-old mice (n = 8 per group) were treated daily for 3 months and
tested in the radial arm water maze (RAWM; A). Chronic cotinine treatment
(5mg/kg) diminished cognitive impairment in the transgenic (Tg) mice as
assessed using the RAWM testing for working memory. This tests revealed
that cotinine-treated Tg mice (Tg + Cot 5) made fewer errors than
vehicle-treated Tg mice (Tg + Veh) when tested overall (∗∗p < 0.01; B) and
during the final block of testing (∗∗p < 0.01; D). Latencies between groups
overall (C) and during the final block (E) are also shown. Tx, treatment; WB,
Western blot.
BEHAVIORAL TESTING
Radial arm water maze (spatial working memory test)
The RAWM test consists of six radially distributed swim arms
emanating from a central circular insert placed into a 100 cm cir-
cular pool and was conducted as previously described (Arendash
et al., 2009; Grizzell et al., 2014). For mice in protocol 1, the
latency and number of errors prior to locating the swim arm
containing a submerged escape platform was determined for 5
trials per day over 8 days of testing. The latency and number of
errors during Trial (T) 4 and T5, which are separated by a 30-min
period, are both considered indices of working memory encod-
ing and recall. The statistical analysis was carried out by analyzing
performance over all 8 days and during the last 3 days (final block)
of the RAWM test.
Porsolt’s forced swim test (depressive-like behavior)
The PT is broadly used to assess depressive-like behavior (Naitoh
et al., 1992). Mice from protocol 3 were placed in a transparent
cylinder filled with water at 25◦C for 5min. Two investigators
blind to all treatment levels independently scored immobility,
which is considered a measure of depressive-like behavior in
rodents (Naitoh et al., 1992; Karl et al., 2003). Immobility is
herein defined as the summation of time when the mouse is con-
sidered motionless in the water, and includes only the movement
necessary to keep its head above the water. Following testing, mice
were hand-dried with a towel and returned to their home cages.
BRAIN TISSUE PREPARATION
For the protein and plaques analyses, mice from protocols 1 and
2 were euthanized and perfused with cold PBS (pH 7.4). The left
frontal half of each brain was placed in 4% paraformaldehyde in
PBS (pH 7.4) overnight, wherein tissues remained until the paraf-
fin embedding process for Aβ IHC analyses. The rest of the brains
were dissected out into regions of interest, quickly frozen, and
stored at −80◦C for neurochemical analyses.
Aβ PLAQUE ANALYSIS
Aβ plaques were analyzed in mice from protocol 2 as previously
described (Arendash et al., 2009). The posterior cortex from the
left side of the brain was dissected. Five coronal sections of paraf-
fin blocks were sectioned at the level of hippocampus and entorhi-
nal cortex (bregma −2.92 to −3.64mm), according to Franklin
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FIGURE 2 | Cotinine reduces Aβ plaques in the hippocampus and
entorhinal cortex of Tg6799 mice. Transgenic (Tg) mice at 4.5–5 months of
age (n = 8 per group) were treated daily for 2 months with vehicle (Veh) or
Cotinine (5mg/kg; Cot 5), euthanized and Aβ immunoreactivity (IR) in the
hippocampus and entorhinal cortex was measured by immunohistochemistry
(IHC; A). Tg mice treated with cotinine (Tg + Cot 5) showed less Aβ plaques in
the hippocampus and entorhinal cortex compared to vehicle-treated Tg mice
(Tg + Veh; B). The photomicrographs to the left are representative views of Aβ
plaques in the hippocampus (Upper ) and entorhinal cortex (Lower ) of brain
sections of Tg mice stained with the Aβ-specific antibody 4G8 (Scale bar =
50μm). The graphs to the right represent the percentage of Aβ plaque burden
in these brain regions. In the hippocampus, a 47% reduction (t = 10.03;
∗∗∗p < 0.001; C) and in the entorhinal cortex, a 45% reduction (t = 16.47;
∗∗∗p < 0.001; D) was found. Tx, treatment.
and Paxinos (Franklin and Paxinos, 2001), and five 5-μm sections
(100μm apart) were made from each mouse brain using a slid-
ing microtome. IHC analyses were performed using a Vectastain
ABC Elite kit (Vector Laboratories, Burlingame, CA) coupled with
the diaminobenzidine reaction, except that the biotinylated sec-
ondary antibody step was omitted for Aβ IHC staining. A biotiny-
lated human Aβ monoclonal antibody (clone 4G8, Covance
Research Products, Emeryville, CA) was incubated for 1 h at
room temperature. PBS (pH 7.4) or normal rabbit serum was
used instead of primary antibody or ABC reagent as a negative
control. Brain sections were treated with 70% formic acid prior
to the pre-blocking step. Quantitative image analysis was con-
ducted as previously described (Tan et al., 2002; Mori et al., 2006)
with modifications. Images were acquired using an Olympus
BX60 microscope with an attached digital camera system (DP-
70, Olympus, Tokyo, Japan), and digital images were routed
into a Windows PC for quantitative analysis using a SimplePCI
software (Hamamatsu Photonics, Hamamatsu, Shizuoka, Japan).
Images of three sections through both anatomic regions of inter-
est (entorhinal cortex and CA1 region of the hippocampus)
were captured from each animal, and a threshold optical density
was obtained that discriminated staining from background. Each
region of interest was manually edited to eliminate artifacts. For
Aβ plaque burden analysis, data is reported as a percentage of the
immunolabeled area (positive pixels) relative to the full area cap-
tured (total pixels). Each analysis was done by a single investigator
blind to sample identities.
ANALYSIS OF Aβ LEVELS
The levels of Aβ40 and Aβ42 in the hippocampi of mice from
protocol 2 were quantified by enzyme-linked immunosorbent
assay (ELISA). To assess soluble Aβ levels, brain tissues were
homogenized in radioimmunoprecipitation assay (RIPA) buffer,
centrifuged at 20,000 × g for 30min and the supernatants
were stored at −80◦C until use. To determine insoluble Aβ, the
detergent-insoluble pellets were homogenized by sonication in a
5M guanidine HCl (pH 8.0) solution (Sigma-Aldrich), incubated
for 3 h in a rocking platform at room temperature and cen-
trifuged at 20,000 × g for 30min at 4◦C. The supernatants were
stored at −80◦C until use or immediately diluted in PBS with
5% bovine serum albumin (Sigma-Aldrich) and 0.03% Tween-
20 supplemented with 1× protease inhibitor cocktail (Roche
Molecular Biochemicals, Indianapolis, IN). These brain extracts
were used for Aβ analysis using ELISA kits (Invitrogen, Carlsbad,
CA) according to the manufacturer’s recommendations.
WESTERN BLOT
Brain tissues from mice in protocol 1 were analyzed by Western
blot as previously described (Echeverria et al., 2009). Brains were
rapidly removed and tissues dissected and disrupted by sonica-
tion in RIPA buffer (Cell Signaling Technology, Danvers, MA)
with a complete protease inhibitor cocktail (Roche Molecular
Biochemicals). Brain extracts were centrifuged at 20,000 × g for
30min at 4◦C. Equal amounts of protein from the supernatant
were separated by electrophoresis using 4–20% Tris-Glycine gel
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FIGURE 3 | Cotinine diminished depressive-like behavior in Tg6799
mice. At 4.5–5 months of age, naïve transgenic (Tg) mice and
non-transgenic (NT) littermates (n = 16 per group) were tested for basal
levels of depressive-like behavior in the Porsolt’s forced swim test (PT-1; A).
Tg mice displayed significantly greater immobility times than NT
counterparts (t = 2.158, df = 30, ∗p = 0.0391; B,C). Following 10 days of
treatment with cotinine (5mg/kg) or vehicle, Tg6799 mice were retested in
the PT (PT-2). Cotinine-treated Tg mice (Tg + Cot 5) showed significantly
less immobility than vehicle-treated Tg (Tg + Veh) cohorts (t = 2.775,
df = 14, ∗p = 0.0149). sec, seconds; Tx, treatment.
(Thermo Fisher Scientific, Rockford, IL). The separated pro-
teins were transferred to nitrocellulose membranes. The mem-
branes were blocked in Tris-buffered saline with 0.05% tween
20 (TBST; Bio-Rad, Richmond, CA) containing 10% dry skim
milk and incubated in TBST with primary antibodies and LI-
COR’s goat IRDye secondary antibodies (LI-COR Biosciences,
Lincoln, NE). Rabbit polyclonal antibodies directed against
PSD95 and phospho-Akt (Ser 473) were obtained from Cell
Signaling Technology. A monoclonal mouse antibody against
β-tubulin (Promega, Madison, WI) was used to control pro-
tein loading and transfer efficiency. Images were acquired using
an Odyssey Infrared Imaging System (LI-COR Biosciences) and
analyzed using the NIH Image J software.
STATISTICAL ANALYSIS
To analyze the group and treatment effects, any violations of the
assumptions of parametric testing were first determined using the
Shapiro–Wilk’s test. Differences of between-groups means in the
behavioral studies were assessed using One-Way and Two-Way
analysis of variance (ANOVA) with post hoc Tukey or Tukey-
Kramer (where applicable) multiple comparison tests used to
identify differences between individual groups. Student’s t-tests
were used when comparing two conditions, such as the PT and
Aβ plaque burden analyses. Western blot data were analyzed using
the Kruskal–Wallis test and were followed by Dunn’s post-hoc test
when appropriate. Differences were considered significant with
p < 0.05.
RESULTS
TREATMENT WITH COTININE IMPROVED SPATIAL WORKING MEMORY
IN Tg6799 MICE AT MORE ADVANCED STAGE OF THE DISEASE
Tg6799mice andNT littermates began treatment at 4.5–5months
of age with vehicle (PBS, pH 7.4) or Cot 5 for which contin-
ued daily for 3 months. Then, under continued treatments, the
effects of cotinine and genotype on spatial and working memory
in the RAWM test were investigated using 2 (genotype)× 2 (treat-
ment) factorial ANOVAs for both errors and latency to find the
submerged platform (Figure 1A). Four experimental groups were
tested: (1) vehicle-treated Tg6799 group (n = 8), (2) vehicle-
treated NT group (n = 8), (3) cotinine-treated Tg6799 group
(n = 8), and (4) the cotinine-treated NT group (n = 7). In the
cotinine-treatedNT group, one animal had sustained injury unre-
lated to RAWM testing or treatment, this mouse was omitted from
the analysis.
The results show that Tg6799 mice were significantly impaired
as compared to NT groups, making more errors across all 8 days
[significant main effect of genotype: F(1, 27) = 19.83; p < 0.0001;
Figure 1B] and in the final 3 days of testing (final block, days 6–8)
[F(1, 27) = 15.52; p = 0.0005; Figure 1D], which is considered to
be more relevant when assessing working memory performance.
Furthermore, the latency to find the hidden platform was also sig-
nificantly affected by genotype across all 8 days [F(1, 27) = 5.343;
p = 0.0287; Figure 1C] and in the final block of testing [F(1, 27) =
6.990; p = 0.0135; Figure 1E].
Cotinine-treatment improved working memory performance
in Tg6799 mice as evidenced by fewer errors to find the sub-
merged platform across all 8 days [significant main effect of
treatment: F(1, 27) = 4.954; p = 0.0346; Figure 1B] and in the
final block [F(1, 27) = 6.196; p = 0.0193; Figure 1D]. However,
there were no significant main effects of treatment detected in the
analyses over latencies to find the platform across all 8 days or in
the final block (Figures 1C,E).
Significant interactions between genotype and treatment lev-
els were uncovered in the analysis of number of errors finding
the platform across all 8 days [F(1, 27) = 13.19; p = 0.0012]. A
Tukey–Kramer’s post-hoc test revealed that this was likely due
to a cotinine-induced normalization of RAWM performance in
Tg6799 mice as there were no differences between cotinine-
treated Tg6799 mice and the vehicle- or cotinine-treated NT
mice, with NT groups not differing from one another either. On
the other hand, vehicle-treated Tg6799 mice made more errors
than vehicle-treated NT mice (p < 0.001), cotinine-treated NT
mice (p < 0.0001), and their cotinine-treated, Tg6799 counter-
parts (p < 0.01; Figure 1B). This was equally true when con-
sidering errors in the final block [interaction: F(1, 27) = 6.726;
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p = 0.0152] as cotinine-treated Tg6799 mice differed only from
vehicle-treated Tg6799 mice (p < 0.01; Figure 1D). Vehicle-
treated Tg6799 mice however, did differ from both NT groups
(both: p < 0.001) andNT groups did not differ from one another.
Taken together, these results confirm that cotinine normalized
the effects of AD-like pathology on spatial and working memory
performance in the RAWM task, which here, is more advanced
than in our previous findings (Echeverria et al., 2011).
EFFECT OF COTININE ON Aβ BURDEN IN THE BRAINS OF Tg6799 MICE
Aβ plaques begin to present in Tg6799 mice around 2 months of
age and progressively increase to be full development at 8 months
of age (Oakley et al., 2006). We have previously shown that coti-
nine prevented the development of these plaques when treatment
begins prior to the onset of pathology development in Tg6799
mice (Echeverria et al., 2011). To investigate whether cotinine
could reduce Aβ plaque deposition at more advances stages of the
disease, Tg6799mice at 4.5–5months of age were evaluated for Aβ
plaque burden in the hippocampus after 2 months of treatment
(6.5–7 months of age at euthanization).
Tg6799 mice showed a robust Aβ plaque burden of 6.5 ±
0.8% in the hippocampus and 9 ± 0.6% in the entorhinal cor-
tex. Compared to the vehicle-treated Tg6799 controls, cotinine-
treated Tg6799 mice exhibited significant lower levels of Aβ bur-
den in both the hippocampus (−47%; t = 10.03; p < 0.001) and
entorhinal cortex (−45%; t = 16.47; p < 0.001) (Figures 2B–D).
EFFECT OF COTININE ON Aβ LEVELS IN THE BRAINS OF Tg6799 MICE
We have also previously shown that treatment with cotinine
(2.5mg/kg) prior to Aβ plaque development (2 months of age)
decreased Aβ plaque burden, the levels of Aβ42, and the ratio of
Aβ42/Aβ40 in the detergent-insoluble fractions of the brains of
Tg6799 mice (Echeverria et al., 2011). In this study, we inves-
tigated whether a two-fold higher dose of cotinine (5mg/kg)
could reduce Aβ42 levels in mice when administered at more
advance stages of the pathology (4–5 months of age, n = 7–8 per
group).
In agreement with our previous findings, we found that
the levels of Aβ42 in the insoluble fraction were substantially
higher than Aβ40 levels in the hippocampus of Tg6799 mice
(Table 1). Insoluble Aβ42 levels were decreased in both the
hippocampus (−29%, t = 1.59, p = 0.14) and cortex (−38%,
t = 2.1, p = 0.056) of cotinine-treated Tg mice when compared
to vehicle-treated Tg6799 mice. A significant decrease in the lev-
els of insoluble Aβ40 was found in the hippocampus (t = 0.447,
p = 0.047), and in the cortex (−56%, t = 2.51, p = 0.03).
In the hippocampus of cotinine-treated Tg6799 mice, with
respect to Tg controls, we found a significant decrease in the
levels of soluble Aβ42 (−54%, t = 2.21, p = 0.049) but a non-
significant difference in soluble Aβ40 peptide levels (+31%, t =
0.02, p = 0.98).
The levels of soluble Aβ peptides in the cortex of Tg mice were
undetectable. A consistent decrease in the ratio of Aβ42/40 in the
soluble (−52%, t = 2.73, p = 0.02) and insoluble fractions of the
hippocampus (−22%, t = 0.68, p = 0.51) was found. Similarly, a
decrease in the Aβ42/Aβ40 ratio was observed in the cortices of
Tg mice, but this difference did not reach significance (−22%,
t = 0.79, p = 0.45).
COTININE DECREASED DEPRESSIVE-LIKE BEHAVIOR IN Tg6799 MICE
It has been previously shown that in addition to apathy,
AD patients have a high incidence of depression (Chung and
Cummings, 2000). Higher levels of depressive-like behavior have
also been observed in Tg AD mice, expressed as increased immo-
bility in the PT (Filali et al., 2009; Hou et al., 2010). Here, we
show that untreated 4.5–5 month-old Tg6799 mice displayed sig-
nificantly greater immobility times than NT littermates in the
PT (t = 2.158, df = 30, p = 0.0391; Figure 3B). We have pre-
viously shown that cotinine reduces depressive-like behavior in
C57BL/6 mice following 1 week of treatment (Grizzell et al.,
2014). However, nothing is known regarding cotinine’s effects
on depressive-like behavior in AD conditions. Following 10 days
of treatment with cotinine (5mg/kg) or vehicle in Tg6799 mice,
cotinine significantly reduced the immobility times of Tg6799
mice (t = 2.775, df = 14, p = 0.0149; Figure 3C).
COTININE STIMULATES THE pAkt/PSD95 PATHWAY IN THE
HIPPOCAMPUS AND FRONTAL CORTEX OF Tg6799 MICE
PSD95 is a synaptic protein and its expression is required for
NMDA-dependent synaptic plasticity. Furthermore, the expres-
sion of PSD95 is decreased in the brains of individuals with
mild cognitive impairment (Sultana et al., 2010). PSD95 expres-
sion can be induced by activation of Akt signaling. Since we
have previously found that cotinine activated Akt, we investigated
Table 1 | Levels of soluble and insoluble Aβ in the hippocampus and frontal cortex of Tg6799 mice.
Soluble (ng/mg) Insoluble (ng/mg)
Hippocampus Aβ42 Aβ40 Aβ42/Aβ40 Aβ42 Aβ40 Aβ42/Aβ40
Vehicle 63 ± 9 29 ± 4 2.5 ± 0.7 1315 ± 124 95 ± 12 66 ± 18
Cotinine 25 ± 11* 20 ± 7 1.2 ± 1.0* 940 ± 191 57 ± 13* 52 ± 13
Cortex Aβ42 Aβ40 Aβ42 Aβ40 Aβ42/Aβ40
Vehicle <0.015 <0.008 784 ± 53 36 ± 7 27 ± 6
Cotinine <0.015 <0.008 492 ± 129† 16 ± 4* 21 ± 5
The data is expressed as the mean ± SD in ng/mg of wet tissue from 6 to 8 mice/condition. Student’s t-test was used to compare the mean of the values between
groups. *p < 0.05; †p = 0.056.
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whether cotinine could trigger PSD95 expression in the hip-
pocampus and frontal cortex. The results of the Kruskal–Wallis
test showed statistically significant differences in Akt phospho-
rylation (pAkt) between groups in the hippocampus [H(2, 14) =
8.197, p = 0.0074] and frontal cortex [H(2, 13) = 7.853, p =
0.0077]. A Dunn’s post-hoc test showed a significant increase in
pAkt in the hippocampus (p < 0.05; Figure 4A) and prefrontal
cortex (p < 0.05; Figure 4B) of cotinine-treated Tg6799 mice
when compared to vehicle-treated Tg6799 mice.
In addition to those observed in pAkt, statistically significant
differences in PSD95 expression were found in the hippocam-
pus [H(2, 14) = 9.686, p = 0.0006] and frontal cortex [H(2, 13) =
8.782, p = 0.0021] by the Kruskal–Wallis test. A Dunn’s post-
hoc test showed a significant increase in PSD95 in the hip-
pocampus (p < 0.01; Figure 4C) and prefrontal cortex (p < 0.01;
Figure 4D) of cotinine-treated Tg6799 mice when compared to
vehicle-treated Tg6799 mice.
DISCUSSION
Alzheimer’s disease (AD) is a progressive neurodegenerative dis-
ease leading to memory and synaptic loss as well as non-cognitive
psychiatric symptoms. Because AD is characterized by a deficit of
cholinergic function, several cholinergic drugs have been tested
including nicotine. Nicotine improved cognitive processes such
as attention in rodents (Decker et al., 1992) and may be neuro-
protective against Aβ toxicity (Brown et al., 2013). The activation
of the α7 nicotinic acetylcholine receptor/phosphatidylinositol 3-
kinase (α7nAChR/PI3K) signaling pathway and a cross talk with
the Wnt signaling pathway seems to mediate nicotine’s posi-
tive effects on memory impairment in TgAPPswe/PS1dE9 mice
(Inestrosa et al., 2013). However, another report showed that
nicotine potentiated the depressive actions of Aβ1−40 on long-
term potentiation in the CA1 region of the hippocampi in rats
(Freir and Herron, 2003). Furthermore, in clinical trials, nico-
tine improved attention but did not show memory enhancing
effects in AD patients (Jones et al., 1992). In addition, many
concerns exist about the risks of using a potentially hazardous
chemical to treat AD patients (Baldinger and Schroeder, 1995).
Similarly, literature surveying the effect of nicotine on depressive-
like behavior is ambivalent with some preclinical studies report-
ing decreased (Djuric et al., 1999; Semba and Wakuta, 2008) or
increased (Hayase, 2007, 2008, 2011, 2013) depressive behavior
with nicotine use.
We have previously shown that cotinine, generated in the
body as a result of nicotine metabolism (Moran, 2012), prevented
cognitive impairment, diminished Aβ plaques, and Aβ oligomer
FIGURE 4 | Cotinine stimulated the Akt/PSD95 pathway in the
hippocampus and frontal cortex of Tg6799 mice. Western blot
analysis of the immunoreactivity (IR) for phosphorylated Akt (pAkt),
PSD95 and tubulin β in the hippocampus and frontal cortex of
vehicle-treated non-transgenic (NT) control mice (NT + Veh),
vehicle-treated transgenic (Tg) mice (Tg + Veh), and cotinine-treated Tg
mice (Tg + Cot 5). Tg + Cot 5 mice had significantly greater levels of
pAkt (∗p < 0.05; A) and PSD95 (∗∗p < 0.01; C) than Tg + Veh
counterparts in the hippocampus. Similarly, Tg + Cot 5 mice showed
higher levels of pAkt (∗p < 0.05; B) and PSD95 (∗∗p < 0.01; D) than Tg
+ Veh controls. The scatter plots with mean and standard deviation
represent the IR of pAkt and PSD95 normalized against tubulin β values
and expressed as percentage of NT control values. Micrographs of the
Western blot images are also included.
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levels in the brains of (5 × FAD) Tg6799 mice (Echeverria et al.,
2011).
In this report, we investigated the effect of cotinine on the pro-
gression of AD-like pathology and depressive-like behavior in the
same strain of AD model mice but at a more advanced stage in
the pathology’s development. Despite this fact, cotinine attenu-
ated working memory impairment, even statistically normalizing
this performance to the levels of both NT groups. Cotinine also
decreased Aβ plaque burden in both the entorhinal cortex and
hippocampus as well as decreased levels of both insoluble and
soluble Aβ40 and Aβ42 peptides in the hippocampus of these
Tg6799 mice. These positive effects were also accompanied by
the stimulation of the Akt/PSD95 pathway in the hippocampus
and frontal cortex of these mice. In addition, cotinine reduced
depressive-like behavior in Tg6799 mice, which extends our pre-
vious findings of the generic antidepressant effects of cotinine in
normal and chronically stressed C57BL/6 mice (Grizzell et al.,
2014) to subjects with AD-like symptoms.
Neuropsychiatric disturbances such as depression are critical
in primary care giving of AD patients. Growing evidence sug-
gests that depression may be both a cause and a consequence
of AD and that antidepressants may be useful against this con-
dition (Hou et al., 2010). There are several hypotheses regard-
ing the cause of depression in AD, including emotional stress
(Meynen et al., 2007), neuroinflammation, and neurodegenera-
tion (Aznar and Knudsen, 2011). A decrease of serotonin (5-HT)
in the brain is considered one of the possible causes of depres-
sion in AD (Modrego, 2010). Previous studies of non-cognitive
behavioral changes in AD model mice showed that they present
neuropsychiatric symptoms such as aggression (Pugh et al., 2007;
Vloeberghs et al., 2007), anxiety (Vloeberghs et al., 2007), and
depressive-like behavior (Filali et al., 2009) similar to the symp-
toms observed in humans. For example, one of these studies has
shown that TgAPPswe/PS1dE9 mice have higher levels of irri-
tability, poorer nest building, and higher immobility times in
the PT compared to NT control littermates (Filali et al., 2009).
Similarly, we observed an increase in immobility in the PT in
Tg6799mice prior to any intervention. Following 10 days of treat-
ment, however, the cotinine-treated mice displayed lower levels
of immobility, which was not attributable to cotinine-induced
changes in locomotor activity (Zeitlin et al., 2012; Grizzell et al.,
2014). The observed decrease in depressive-like behavior induced
by cotinine is intriguing considering that depression is the main
non-cognitive symptom observed in AD (Aznar and Knudsen,
2011; Barber, 2011), and that current antidepressants typically
fail to bolster its detrimental effects in these patients (Modrego,
2010; Weintraub et al., 2010) likely due to an alternative eti-
ology or mechanism underlying its development from non-AD
sufferers (Hollingworth et al., 2006). It has been demonstrated
that cotinine increases 5-HT levels in the rat brains (Fuxe et al.,
1979) and it is therefore possible that the antidepressant effects
of cotinine are partially mediated by an increase in 5-HT levels
in the brain. Also, 5-HT does exert positive effects on mem-
ory, seemingly mediated by a subset of 5-HT receptors such as
5-HT1A, 5-HT4, and 5-HT6 (King et al., 2008). Although these
are plausible ideas, selective serotonin reuptake inhibitors (SSRIs)
have not shown beneficial effects in AD patients in clinical trials
(Modrego, 2010). Thus, some of the beneficial effects of cotinine
could be due to the stimulation of serotonergic activity but may
act through additional mechanisms which facilitate and supple-
ment its antidepressant and pro-cognitive effects in AD model
mice.
AD is characterized by deficits of memory processes (Stone
et al., 2011). This has been mimicked in animal models of the
disease as well (Oakley et al., 2006; Ohno et al., 2006). We have
previously shown that when administered prior to Aβ plaque
pathology development in Tg6799 mice, at 2 months of age,
cotinine-treatment prevented AD-induced impairment of work-
ing memory in the RAWM task, a powerful measure of working
memory in rodents (Echeverria et al., 2011). When treatment
began at more advanced stages of this disease (∼5 months), the
current results show that cotinine treatment also normalized the
performance in the RAWM to the levels of NT animals at an age
when Tg6799 mice would present abundant Aβ plaque pathol-
ogy (∼8 months) and cognitive impairment (Oakley et al., 2006).
This is particularly encouraging as memory impairments are at
the forefront of AD symptomology. Furthermore, despite recent
advances in detecting early Aβ plaque pathology, it is not always
possible to identify individuals who will suffer from dementia and
AD prior to the disease’s development, therefore finding effective
therapies in reducing cognitive impairment after the pathology
has advanced to middle stages is crucial.
Episodic memory involves the capacity to learn, store, and
retrieve information about experiences such as when (time),
where (place), and what (event). AD patients in early stages of the
pathology present with severe deficits in episodic memory. The
circuits supporting episodic memory are highly conserved across
mammalian species from rodents to primates and involves neo-
cortical association areas, the parahippocampal region, and the
hippocampus (Eichenbaum, 2006). RAWM test is broadly used
to determine memory deficits in transgenic AD mice. RAWM is
dependent on hippocampus activity, and it is generally accepted
to be a sensitive test for short-term episodic memory (Savonenko
et al., 2005).We have previously shown that cotinine administered
at early stages of the pathology prevented short-term episodic and
reference memory impairment in Tg6799 mice. Here, we report
that depressive-like behavior in Tg6799 mice appears early dur-
ing the pathology and continues at more advanced stages. In our
model, cotinine reduced depressive-like behavior at all stages of
the pathology. Thus, it is reasonable to speculate that the preven-
tion of memory loss by cotinine in our first studymay also involve
a decrease in depressive-like behavior at early stages of the pathol-
ogy. However, further experiments are required to confirm this
idea.
In addition to its enhancement of cognitive and non-cognitive
symptoms, cotinine decreased Aβ plaque burden and the levels of
Aβ40/42 peptides in the brains of Tg6799 mice. These effects mir-
rored the observed decrease in Aβ plaques and levels of soluble
Aβ peptides accumulating in the brain induced by pretreatment
with cotinine (2.5mg/kg) (Echeverria et al., 2011). This time,
when mice were treated at later stages of the disease, the beneficial
effect in reducing plaque pathology was higher than in the previ-
ous study. In our previous study, a 5-month cotinine (2.5mg/kg)
treatment beginning at 2 months of age resulted in reduced Aβ
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plaque size at an average of 26 and 17% in the cingulate andmotor
cortices, respectively (Echeverria et al., 2011). Instead, when treat-
ment was delayed until ∼5 months of age, 2 months of treatment
with cotinine (5mg/kg) reduced Aβ plaque burden by 47 and
45% in the hippocampus and entorhinal cortex, respectively. This
enhanced effect may be the result of the increased dosage used.
However, it is important to consider that at later stages of AD-
like pathology, the rate of Aβ plaque burden progression is much
faster. Thus, we would expect to observe higher differences in
percentage of Aβ plaque burden with a drug that halts the aggre-
gation of the Aβ peptides at middle stages of the disease. Also,
we may consider that the size of the Aβ plaques at the age tested
in both studies (∼8 months of age) were lower in the cingulate
and motor cortices than the observed in the hippocampus and
entorhinal cortex in Tg6799 mice. This difference further compli-
cates the interpretation as a lower development of Aβ plaques in
the former regions will result in a slower building of Aβ plaques,
thus resulting in lower differences with the mice treated with
cotinine (2.5mg/kg) beginning at 2 months. Independent of the
previous considerations, the results clearly showed that cotinine
can not only slow down or prevent Aβ plaque development when
it is administered at early stages of the disease, but can also halt
its progression at later stages. Further studies are required to
assess whether cotinine may also facilitate the clearance of the Aβ
plaques. On the other hand, the analyses of the Aβ levels show
that treatment with cotinine at the later stage, even at a higher
dose, results in higher levels of insoluble and soluble Aβ42 pep-
tides than mice treated at the early stage of the disease (Echeverria
et al., 2011). It is interesting that in spite of these higher levels
of Aβ peptides in the hippocampus, a significant positive effect
over cognition was still attained in the cotinine-treatedmice when
compared to vehicle-treated mice. This permits us to suggest
that cotinine may have an additional mechanism supporting its
neuroprotective effect other than reducing Aβ aggregation.
Neuroinflammation and a decrease of neurotrophic factors
levels in the brain are considered key factors inducing synaptic
loss and a common link between depression and AD (Wuwongse
et al., 2010). Morphological studies have shown that a significant
correlation exists between memory performance and synaptic
plasticity during memory consolidation, and the loss of synap-
tic spines correlates with cognitive impairment in AD (Pozueta
et al., 2013). Therefore, the enhancement of synaptic function
may be fundamental to restore cognitive abilities and mood in
neurodegenerative conditions, including AD (Yu and Lu, 2012).
We have previously shown that cotinine induces increases in
synaptophysin, a synaptic protein serving as a marker for synap-
tic density, and decreased depressive-like behavior induced by
chronic stress in mice (Grizzell et al., 2014). Consistent with this
idea, we found that cotinine diminished depressive-like behav-
ior, increased cognitive abilities, and enhanced the expression of
synaptic protein PSD95 in the hippocampus and frontal cortex of
Tg6799 mice. PSD95 plays a key role promoting brain plasticity
by controlling NMDA receptor signaling (Wang et al., 2012). A
previous study showed that extracellular signal-regulated kinase
(ERK)-dependent PSD95 induction in the gustatory cortex was
an essential step in taste learning (Elkobi et al., 2008). A more
recent study has shown that other natural products such as
the ginkgo flavonols, quercetin, and kaempferol, stimulated the
brain-derived neurotrophic factor (BDNF)/cyclic AMP response
element binding protein/PSD95 pathway and reduced Aβ in neu-
rons isolated from TgAPPswe/PS1dE9 mice (Hou et al., 2010).
The synthesis of PSD95 is a process that occurs at the synapse
and its mRNA is abundant in the neuropil regions along with
other dendritic proteins such as dendrin and the microtubule-
associated protein 1A (Cajigas et al., 2012). It has been shown that
BDNF promotes translation of specific mRNAs including PSD95
by regulating the activity of the protein synthesis machinery.
Expression of long-lasting synaptic plasticity and long-term
memory requires protein synthesis, especially since some mRNAs
of synaptic proteins are already located at the synapse wait-
ing for translation at the ribosome. The translation of PSD95
is promoted by the phosphorylation of the modulators of pro-
tein translation eukaryotic translation initiation factor 4E (eIF4E)
and eukaryotic translation initiation factor 4E binding protein 1
(4EBP1) by activating the ERK and PI3K/Akt signaling pathways,
respectively (Leal et al., 2014). PI3K/Akt/mTOR (mammalian
target of rapamycin)-cAMP response element-binding protein
(CREB) and ERK-dependent signaling pathways modulate the
protein translation efficiency necessary for establishing long-term
synaptic plasticity (Kelleher et al., 2004). Alterations in Akt phos-
phorylation, mTOR activity and its downstream targets 4E-BP1,
eukaryotic elongation factor 2 (eEF2), and eEF2 kinases have been
found in AD brains (Li et al., 2005). Although it is controversial,
it has been reported that there is a decrease in mTOR signaling in
the brains of AD mice (Caccamo et al., 2013; Gouras, 2013; Tang
et al., 2013) and AD patients (Lafay-Chebassier et al., 2005; Pei
and Hugon, 2008; Sun et al., 2014). Moreover, the inhibition of
mTOR signaling correlates with impairment in synaptic plasticity
in hippocampal slices from an ADmouse model and in wild-type
slices exposed to exogenous Aβ. The activation of mTOR may
rescue cognitive impairment, as its up-regulation through GSK3
inhibitors rescued long-term potentiation, a cellular model of
synaptic plasticity, in a mouse model of AD (Ma et al., 2010). The
authors concluded that the mTOR pathway modulates Aβ-related
synaptic dysfunction in AD (Ma et al., 2010).
Our data confirms previous results showing that cotinine acti-
vates Akt in the hippocampus and showed for the first time that
this activation corresponds with an increase in the expression of
PSD95 in the brain of Tg6799 mice. Our results are also in agree-
ment with another study showing that antidepressants increased
PSD95 in the hippocampi of TgAPPswe/PS1dE9 mice (Hou et al.,
2010).
Cotinine-induced Akt activation can be the outcome of the
enhancement of cholinergic neurotransmission, which would
favor synaptic function. The α7 and α4β2 nAChRs are the
most abundant nicotinic receptors in the brain. These nicotinic
receptors are broadly expressed in brain regions such as the
amygdala, prefrontal cortex, hippocampus, hypothalamus, and
striatum involved in emotional responses, learning, and mem-
ory. Furthermore, nAChRs may influence depressive behavior
by controlling dopaminergic, serotoninergic, glutamatergic, and
γ-aminobutyric acid neurotransmission. A deficit in nicotinic
receptors is considered a key player in AD pathophysiology (James
and Nordberg, 1995). AD patients have a reduction in cortical
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nicotinic cholinergic receptor when compared to age-matched
control individuals (Flynn and Mash, 1986; Whitehouse et al.,
1986; Aubert et al., 1992; Freedman et al., 1995).
Cotinine is a poor agonist of nAChRs but may act as a positive
allosteric modulator (PAM) of α7nAChRs. As a PAM, cotinine
will not have agonistic effect over the receptors but will enhance
its activation by agonists (Oddo, 2012). This idea explains recent
evidence that both the improvement of sensorimotor desensi-
tization (Vainio et al., 2000; Wildeboer-Andruda et al., 2014)
and fear extinction induced by cotinine (de Aguiar et al., 2013)
depended on the activation of α7 and α4β2nAChRs subtypes. In
addition, previous evidence suggests that cotinine, by stimulat-
ing the α4β2nAChRs and/or α6β2nAChRs, may evoke the release
of DA in a calcium-dependent manner in the striatum (Dwoskin
et al., 1999). Since the striatum is part of the neuronal network
supporting working memory (Spencer et al., 2012), the stimu-
lation of dopamine release can be an additional mechanism by
which cotinine may be influencing learning and memory.
A recent study highlighted the importance of the stimula-
tion of calcium signaling through α7nAChRs (Cheng and Yakel,
2014). The presence of α7nAChRs and the effect of its stim-
ulation in mossy fibers on the hippocampus stimulation were
investigated. The authors expressed the genetically encoded cal-
cium indicator GCaMP3 in dentate gyrus granule cells and used a
PAM of α7nAChRs to diminish the desensitization of the receptor
and enhance calcium signaling. By comparing calcium responses
in wild-type and α7nAChR knock-out mice, they demonstrated
that α7nAChR-dependent calcium currents enhanced glutamate
release at the mossy fiber terminals projecting to the CA3 region
of the hippocampus (Cheng and Yakel, 2014). The importance
of the stimulation of increased intracellular calcium levels by
α7nAChRs for neurotransmitter release probability was also indi-
cated by paired-pulse facilitation plasticity studies.
Based on this evidence, we hypothesize that cotinine facilitates
α7nAChR-mediated increase in calcium concentration which
stimulates Akt activation by PI3K and/or calcium/calmodulin-
dependent protein kinase kinase (CaMKK). Once activated, Akt
can inhibit GSK3β and phosphorylate mTOR or CREB, favor-
ing the expression of PSD95 at the synapse as well as reducing
synaptic loss. The increase in PSD95 will have a positive effect
on synaptic plasticity underlying learning and memory processes
as well as mood stability. Thus, a cotinine-induced increase in
the translation of synaptic proteins at the synapse may prevent
or halt the deficits in synaptic plasticity in AD brains, simulta-
neously improving both cognitive abilities and mood in Tg6799
mice (Figure 5).
Overall, we showed that cotinine halted the cognitive and
depressive-like symptoms of AD at later stages of the disease’s
progression. The beneficial actions of cotinine were accompa-
nied by the stimulation of the Akt/PSD95-CREB pathway in AD
brains. Since this pathway promotes synaptic plasticity and pre-
vents synaptic loss, we conclude that cotinine may prevent and
reduce AD pathology by mitigating synaptic dysfunction in the
hippocampus and frontal cortex in Tg6799 mice. These results
FIGURE 5 | Diagram representing the potential cell signaling pathways
underlying the positive actions of cotinine on synaptic plasticity and
behavior. The α7nAChRs can stimulate Akt (aka, protein kinase B) through
the calcium-dependent activation of CaMKK, which can activate Akt that in
turn phosphorylates and stimulates CREB and/or the mammalian target of
rapamycin (mTOR) activity. The α7nAChR may also stimulate Akt through
ERK/PI3K, and CREB and mTOR phosphorylation. mTOR, and CREB are
serine threonine kinase, that regulate synaptic plasticity and memory
formation. Also, mTOR positively controls the translational machinery to
synthesize synaptic proteins such as PSD95 by stimulating the
phosphorylation of the protein translation modulators eIF4E and 4EBP1.
Therefore, cotinine may enhance the translation of PSD95 by activating
ERK/PI3K/Akt and/or CamKK/Akt signaling pathways via positively modulating
α7nAChR.
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are related to a model of FAD linked to genetic mutations in
both the APP and the PS1 genes. The Tg6799 mouse model of
AD develops Aβ plaques and several behavioral aspects of the
disease, including working memory deficits and depressive-like
behavior as well as presents neurochemical changes observed in
AD brains. However, more than 95% of AD cases are sporadic
(SAD) with a late onset and <5% of AD cases are FAD with an
early onset. The causes of SAD are not well understood, thus,
it is possible that the observed neurochemical changes between
SAD and FAD may differ. However, the cholinergic and synaptic
deficits are common characteristic to both SAD and FAD and the
changes induced by cotinine through the improvement of cholin-
ergic function and nAChRs signaling are likely to occur in both
SAD and FAD. More importantly, brain senescence is a common
link between both types of AD. The senescence hypothesis links
the progression of AD to changes in energy metabolism, Ca2+
deregulation, apoptosis (Mattson, 2007), and neuroinflammation
(Verri et al., 2012).
Cotinine can be an excellent therapeutic agent alone or in com-
bination with other current or future medications because it has
minor side effects in humans. Considering the increasing neces-
sity and world-wide demand of new drugs to prevent, slow down,
or ideally, halt AD, the testing of cotinine in well-designed clinical
studies is urgently needed.
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